Betta Pharmaceuticals Co., Ltd.
300558.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.5B
Close$
$-23.50
154.4% downside
Current Fair Value
154.4% downsideOvervalued by 154.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.50 Billion |
|---|---|
| Enterprise Value | $22.48 Billion |
| Dividend Yield | $0.15 (0.31%) |
| Earnings per Share | $0.73 |
| Beta | 0.43 |
| Outstanding Shares | 420,733,843 |
Return
| Return on Equity | 7.06% |
|---|---|
| Return on Assets | 4.54% |
| Return on Invested Capital | 7.55% |
Valuation & Multiples
| P/E Ratio | 43.54 |
|---|---|
| PEG | 65.62 |
| Price to Sales | 4.8 |
| Price to Book Ratio | 2.88 |
| Enterprise Value to Revenue | 5.83 |
| Enterprise Value to EBIT | 36.13 |
| Enterprise Value to Net Income | 48 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
$0.12
Average shareholder expectationRevenue Estimate
$1.02 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.39
Average shareholder expectationRevenue Estimate
$1.07 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Betta Pharmaceuticals Co., Ltd.
1,785 employees
CEO: Lieming Ding Betta Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of oncology treatments. Among its key offerings are Icotinib hydrochloride, an orally taken...